Establishing the optimal dose of nitric oxide in acute vasoreactivity testing in patients with pulmonary hypertension with use of the Bronchial Control Treatment System (RCD code: II)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2015, Vol 2, Issue 4
Abstract
The key point in the diagnostic algorithm for pulmonary hypertension plays the pulmonary reactivity testing, the agent most frequently used in the test is inhaled nitric oxide (iNO). Various dosages of iNO were used in acute vasoreactivity testing so far, so we aimed to determine the most effective dose of iNO administered in the acute vasoreactivity testing. Ten consecutive patients was enrolled to the open label study. To assess the most effective dose of iNO increasing concentrations of iNO: 10 ppm, 20 ppm and 30 ppm were administered. In the study statistically significant reduction in mean pulmonary artery pressure after each dose of iNO as compared to baseline was found. There were no significant differences in mean pulmonary artery pressure between subsequent iNO doses (10 ppm vs. 20 ppm, 20 ppm vs. 30 ppm). Statistically significant reduction of systolic pulmonary artery pressure after iNO at the dose of 20 ppm as compared to a dose of 10 ppm was observed. No significant side effects during iNO administration were observed. We concluded that the dose of inhaled nitric oxide used in the acute vasoreactivity testing should not exceed 20 ppm, it is effective and safe dose.
Authors and Affiliations
Magdalena Kaznica-Wiatr, Maria Olszowska, Piotr Podolec
Keywords
Related Articles
- EP ID EP242019
- DOI 10.20418/jrcd.vol2no4.189
- Views 114
- Downloads 0
Journal of Rare Cardiovascular Diseases: All that glitters is not gold. Randomized Controlled Trails versus real‑life patients: Challenges of a maturing Journal
Dear Readers,Is time friend or foe? No one has the right answer. With this issue, we are celebrating an important landmark in the Journal’s history. On this occasion, we have looked back at our first two years with a pin...
Brugada syndrome: new concepts and algorithms in management (RCD code: V‐1A.1)
Clinical manifestation of Brugada syndrome (BrS) mainly results from polymorphic ventricular arrhythmias and includes sudden cardiacarrest (SCA). The Brugada sign, besides being present in true BrS, may result from diffe...
Right atrial myxoma in a patient with Budd‐Chiari syndrome
Budd‐Chiari syndrome (BCS) is a rare clinical disorder which is caused by obstruction of the major hepatic veins or suprahepatic portion of the inferior vena cava. Either thrombosis or a mechanical venous obstruction may...
A 50-year-old unrepaired patient with pulmonary atresia and ventricular septal defect
Pulmonary atresia with ventricular septal defect (PA + VSD) is a cyanotic congenital heart disease, also classified as Tetralogy of Fallot with pulmonary atresia. PA + VSD accounts for about 1–2% of congenital heart defe...
Thrombosis within Glenn anastomosis (RCD code: IV-1D.1b)
Thrombosis secondary to Glenn anastomosis in Ebstein’s anomaly has been reported very rarely, treatment depends on presenting symptoms and risk factors. In this article we presented the case of 63-year-old woman with Ebs...